QuidelOrtho Showcases Innovative Diagnostic Solutions at 2025 J.P. Morgan Healthcare Conference

Innovating Diagnostics: QuidelOrtho's Commitment to Healthcare Transformation

QuidelOrtho Corporation, a prominent leader in in-vitro diagnostic technologies, announces its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. Scheduled for January 13, 2025, the company plans to showcase its innovative solutions tailored for point-of-care settings, clinical laboratories, and transfusion medicine. This platform allows QuidelOrtho to demonstrate its commitment to advancing diagnostics, emphasizing the importance of transforming complex data into actionable insights for healthcare providers. The presentation is expected to attract significant attention from industry stakeholders interested in the latest advancements in diagnostic technologies.

At the core of QuidelOrtho's offerings are its immunoassay and molecular testing solutions, which provide fast and reliable results essential for clinical decision-making. These diagnostic tools empower patients, clinicians, and health officials to swiftly identify health trends and respond effectively. By ensuring accuracy and speed in diagnostics, QuidelOrtho plays a vital role in enhancing healthcare outcomes. The company’s focus on clinical chemistry and transfusion medicine further underscores its commitment to comprehensive healthcare solutions that address diverse medical needs.

QuidelOrtho’s innovative approach positions it as a key partner across the healthcare continuum, aiming to reshape the diagnostic landscape on a global scale. The company is dedicated to illuminating a more informed path for healthcare through the seamless integration of expertise and insights. This commitment extends beyond diagnostics; it aims to foster a healthier future for communities worldwide. By participating in significant healthcare events like the J.P. Morgan Conference, QuidelOrtho reinforces its leadership role in the diagnostics sector and its dedication to delivering transformative healthcare solutions.

In addition to the J.P. Morgan Healthcare Conference, stakeholders and industry watchers can access a live webcast of QuidelOrtho’s presentation through the “Events & Presentations” section of its Investor Relations webpage. This availability reflects the company's transparency and engagement with its audience, ensuring that valuable insights into its innovations are widely shared.

QuidelOrtho continues to prioritize advancements in healthcare technology, striving to connect expertise with actionable insights. As the company prepares for its upcoming presentation, it remains focused on its mission to enhance diagnostic capabilities and improve health outcomes across the globe. For further details, stakeholders are encouraged to visit the company’s website at www.quidelortho.com.